These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26512827)

  • 21. Tei index in fabry disease.
    Niemann M; Breunig F; Beer M; Hu K; Liu D; Emmert A; Herrmann S; Ertl G; Wanner C; Takenaka T; Tei C; Weidemann F
    J Am Soc Echocardiogr; 2011 Sep; 24(9):1026-32. PubMed ID: 21719255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional abnormalities of myocardial deformation in patients with hypertrophic cardiomyopathy: correlations with delayed enhancement in cardiac magnetic resonance.
    Ghio S; Revera M; Mori F; Klersy C; Raisaro A; Raineri C; Serio A; Pasotti M; Visconti LO
    Eur J Heart Fail; 2009 Oct; 11(10):952-7. PubMed ID: 19789398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertrophic cardiomyopathy mimicking STEMI: The role of cardiac magnetic resonance imaging in the detection of microvascular coronary dysfunction.
    Raissuni Z; Doghmi N; Mousseaux E; Cherti M; Redheuil A
    Diagn Interv Imaging; 2014 Nov; 95(11):1111-2. PubMed ID: 24560523
    [No Abstract]   [Full Text] [Related]  

  • 24. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy.
    De Cobelli F; Esposito A; Belloni E; Pieroni M; Perseghin G; Chimenti C; Frustaci A; Del Maschio A
    AJR Am J Roentgenol; 2009 Mar; 192(3):W97-102. PubMed ID: 19234246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiological follow-up in patients with Fabry disease].
    Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
    G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy.
    Smith BM; Dorfman AL; Yu S; Russell MW; Agarwal PP; Mahani MG; Lu JC
    Am J Cardiol; 2014 Apr; 113(7):1234-9. PubMed ID: 24513464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.
    Małek ŁA; Werys K; Kłopotowski M; Śpiewak M; Miłosz-Wieczorek B; Mazurkiewicz Ł; Petryka-Mazurkiewicz J; Marczak M; Witkowski A
    Magn Reson Imaging; 2015 Jul; 33(6):718-24. PubMed ID: 25863138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stress hypoperfusion and tissue injury in hypertrophic cardiomyopathy: spatial characterization using high-resolution 3-tesla magnetic resonance imaging.
    Tyan CC; Armstrong S; Scholl D; Stirrat J; Blackwood K; El-Sherif O; Thompson T; Wisenberg G; Prato FS; So A; Lee TY; Drangova M; White JA
    Circ Cardiovasc Imaging; 2013 Mar; 6(2):229-38. PubMed ID: 23413422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Anderson-Fabry disease in a cohort with unexplained late gadolinium enhancement on cardiac MRI.
    Moonen A; Lal S; Ingles J; Yeates L; Semsarian C; Puranik R
    Int J Cardiol; 2020 Apr; 304():122-124. PubMed ID: 31987665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications.
    Payá E; Marín F; González J; Gimeno JR; Feliu E; Romero A; Ruiz-Espejo F; Roldán V; Climent V; de la Morena G; Valdés M
    J Card Fail; 2008 Jun; 14(5):414-9. PubMed ID: 18514934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac challenges in patients with Fabry disease.
    Weidemann F; Linhart A; Monserrat L; Strotmann J
    Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute Myocarditis Complicating Systemic Lupus Erythematosus: Detection and Evolution of Transmural Spiral Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging.
    Kikuchi N; Watanabe E; Nagao M; Yoshizawa S; Kobashigawa T; Hagiwara N
    Circ Cardiovasc Imaging; 2021 Feb; 14(2):e011319. PubMed ID: 33586448
    [No Abstract]   [Full Text] [Related]  

  • 34. Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy.
    Nojiri A; Hongo K; Kawai M; Komukai K; Sakuma T; Taniguchi I; Yoshimura M
    J Cardiol; 2011 Nov; 58(3):253-60. PubMed ID: 21890327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertrophic cardiomyopathy with restrictive phenotype and myocardial crypts.
    Cannavale A; Ordovás KG; Rame EJ; Higgins CB
    J Thorac Imaging; 2010 Nov; 25(4):W121-3. PubMed ID: 20463612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myocardial fibrosis evaluated by Look-Locker and late gadolinium enhancement magnetic resonance imaging in apical hypertrophic cardiomyopathy: association with ventricular tachyarrhythmia and risk factors.
    Amano Y; Takeda M; Tachi M; Kitamura M; Kumita S
    J Magn Reson Imaging; 2014 Aug; 40(2):407-12. PubMed ID: 24924216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of combined late gadolinium enhancement on cardiovascular magnetic resonance and peak oxygen consumption in ambulatory patients with nonischemic dilated cardiomyopathy.
    Yamada T; Hirashiki A; Okumura T; Adachi S; Shimazu S; Shimizu S; Morimoto R; Takeshita K; Naganawa S; Kondo T; Murohara T
    J Card Fail; 2014 Nov; 20(11):825-32. PubMed ID: 25151210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis.
    Iles LM; Ellims AH; Llewellyn H; Hare JL; Kaye DM; McLean CA; Taylor AJ
    Eur Heart J Cardiovasc Imaging; 2015 Jan; 16(1):14-22. PubMed ID: 25354866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnetic resonance imaging of hypertrophic cardiomyopathy.
    Cannavale A; Ordovás KG; Higgins CB
    J Thorac Imaging; 2013 Jan; 28(1):W12-8. PubMed ID: 20827222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease.
    Di Bella G; Pizzino F; Minutoli F; Zito C; Donato R; Dattilo G; Oreto G; Baldari S; Vita G; Khandheria BK; Carerj S
    Eur Heart J Cardiovasc Imaging; 2014 Dec; 15(12):1307-15. PubMed ID: 25190073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.